Brief: Biontech And Bristol Myers Squibb Report Encouraging Global Phase 2 Data For Pumitamig In Advanced Nsclc After Progression On Immunotherapy Plus Chemotherapy
Sun 07:31
BRIEF-Biontech And Bristol Myers Squibb Report Encouraging Global Phase 2 Data For Pumitamig In Advanced Nsclc After Progression On Immunotherapy Plus Chemotherapy Oct 25 (Reuters) - BioNTech SE 22UAy.DE:
BIONTECH AND BRISTOL MYERS SQUIBB REPORT ENCOURAGING GLOBAL PHASE 2 DATA FOR PUMITAMIG IN ADVANCED NSCLC AFTER PROGRESSION ON IMMUNOTHERAPY PLUS CHEMOTHERAPY
Source text: ID:nGNE1r7XPh
Further company coverage: [22UAy.DE]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioNTech SE
See all newsBrief: Biontech And Dualitybio Announce Topline Results Of Global Phase 3 Clinical Trial for Breast Cancer
Brief: Biontech And Bristol Myers Squibb Report Encouraging Global Phase 2 Data For Pumitamig In Advanced Nsclc After Progression On Immunotherapy Plus Chemotherapy
BioNTech, Gilead to test drug combination in advanced breast cancer trial
Brief: BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer
Brief: Biontech To Showcase Oncology Late-Stage Pipeline Progress At ESMO 2026